Boston Scientific (NYSE:BSX) Surprises With Q2 CY2026 Sales But Quarterly Revenue Guidance Misses Expectations
Boston Scientific (NYSE:BSX) Surprises With Q2 CY2026 Sales But Quarterly Revenue Guidance Misses Expectations Medical system firm Boston Scientific (NYSE:BSX) reported Q2 CY2026 outcomes topping the market’s income expectations, with gross sales up 7.5% 12 months on 12 months to $5.44 billion. On the opposite hand, subsequent quarter’s income steering of $5.27 billion was much…